comparemela.com
Home
Live Updates
Nct04526106 - Breaking News
Pages:
Latest Breaking News On - Nct04526106 - Page 1 : comparemela.com
Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors
Lirafugratinib demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer.
Sloan kettering
Alisonm schram
Don bergstrom
International conference on molecular
Molecular targets
Relay therapeutics
Memorial sloan kettering
Bayesian optimal interval
Precision medicine in oncology
News
Nct04526106
2023 aacr nci eortc international conference on molecular targets and cancer therapeutics
RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma
Mitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.
Arizona
United states
Phoenix
Mayo clinic comprehensive cancer center
Treatment options for the management of patients with cholangiocarcinoma
Rly 4008
Refocus trial
Nct04526106
Miteshj borad
D
Mayo clinic
Topaz 1 trial
Nct03875235
Antoine hollebecque
Gustave roussy cancer center
vimarsana © 2020. All Rights Reserved.